Advertisement

Using Continuous Glucose Monitoring for Patients with Fulminant Type 1 Diabetes

Chapter

Abstract

Fulminant type 1 diabetes is temporarily categorized as idiopathic type 1 diabetes mellitus (type 1B). It is characterized by an abrupt onset of the disease mostly with ketosis and ketoacidosis, accompanied by severe metabolic disorder, remarkably elevated blood glucose concentration, and almost complete, irreversible loss of islet function. In severe cases, the disease causes serious complications such as rhabdomyolysis, acute renal failure, and cerebral edema. Fulminant type 1 diabetes most commonly occurs in Asian countries. Timely diagnosis and treatment are the keys to improve the prognosis of patients. As a novel glucose monitoring technology, continuous glucose monitoring (CGM) is helpful to optimize the treatment regimen. This chapter will first briefly introduce fulminant type 1 diabetes with regard to the basic concept, diagnostic criteria, epidemiology, pathogenesis, clinical features, treatment, and prognosis. Also, we will continue to explain how CGM can be used to analyze the characteristics of blood glucose variability in fulminant type 1 diabetes and to guide the adjustment of individualized treatment through the presentation and analysis of typical cases.

Keywords

Type 1 diabetes mellitus Fulminant type 1 diabetes Continuous glucose monitoring 

References

  1. 1.
    Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 2000;342:301–7.  https://doi.org/10.1056/NEJM200002033420501.CrossRefPubMedGoogle Scholar
  2. 2.
    Deng D, Xia L, Chen M, Xu M, Wang Y, Wang C. A case of fulminant type 1 diabetes associated with acute renal failure. Neuro Endocrinol Lett. 2015;36:115–8.PubMedGoogle Scholar
  3. 3.
    Zhou J, Bao YQ, Li M, Liu F, Chen HB, Han JF, Lu W, Ma XJ, Hu C, Xiang KS, Jia WP. Fulminant type 1 diabetes: the clinical features and treatment strategy. Chin J Diabetes Mellitus. 2009;1:34–8.  https://doi.org/10.3760/cma.j.issn.1674-5809.2009.01.011.CrossRefGoogle Scholar
  4. 4.
    Dong H, Liu L, Zhou Y, Mu J, Zhang J. Sudden death of a 15-year-old girl due to fulminant type 1 diabetes mellitus-diabetic ketoacidosis induced cerebral edema? J Forensic Legal Med. 2014;26:5–9.  https://doi.org/10.1016/j.jflm.2014.05.001.CrossRefGoogle Scholar
  5. 5.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):5–20.Google Scholar
  6. 6.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.CrossRefGoogle Scholar
  7. 7.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.  https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMedGoogle Scholar
  8. 8.
    American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl 1):1–135.Google Scholar
  9. 9.
    Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3:536–9.  https://doi.org/10.1111/jdi.12024.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Imagawa A, Hanafusa T. Series: clinical study from Japan and its reflections; a nationwide survey of fulminant type 1 diabetes. Nippon Naika Gakkai Zasshi. 2013;102:1829–35.CrossRefGoogle Scholar
  11. 11.
    Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50:2276–9.  https://doi.org/10.1007/s00125-007-0812-z.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.  https://doi.org/10.1111/j.2040-1124.2011.00139.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab. 2006;91:471–6.  https://doi.org/10.1210/jc.2005-1943.CrossRefPubMedGoogle Scholar
  14. 14.
    Kwak SH, Kim YJ, Chae J, Lee CH, Han B, Kim JI, Jung HS, Cho YM, Park KS. Association of HLA genotype and fulminant type 1 diabetes in Koreans. Genomics Inform. 2015;13:126–31.  https://doi.org/10.5808/GI.2015.13.4.126.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zheng C, Zhou Z, Yang L, Lin J, Huang G, Li X, Zhou W, Wang X, Liu Z. Fulminant type 1 diabetes mellitus exhibits distinct clinical and autoimmunity features from classical type l diabetes mellitus in Chinese. Diabetes Metab Res Rev. 2011;27:70–8.  https://doi.org/10.1002/dmrr.1148.CrossRefPubMedGoogle Scholar
  16. 16.
    Jung JH, Hahm JR, Kim MA, Park MH, Kim DR, Jung TS, Chung SI. Fulminant autoantibody-negative and type 1A diabetes phenotypes in a Korean HLA identical dizygotic twin. Diabetes Care. 2005;28:2330–1.CrossRefGoogle Scholar
  17. 17.
    Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345–52.CrossRefGoogle Scholar
  18. 18.
    Imagawa A, Hanafusa T, Makino H, Miyagawa JI, Juto P. High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia. 2005;48:290–3.  https://doi.org/10.1007/s00125-004-1624-z.CrossRefPubMedGoogle Scholar
  19. 19.
    Imagawa A, Hanafusa T. Fulminant type 1 diabetes--an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27:959–64.  https://doi.org/10.1002/dmrr.1236.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanaka S, Aida K, Nishida Y, Kobayashi T. Pathophysiological mechanisms involving aggressive islet cell destruction in fulminant type 1 diabetes. Endocr J. 2013;60:837–45.CrossRefGoogle Scholar
  21. 21.
    Minegaki Y, Higashida Y, Ogawa M, Miyachi Y, Fujii H, Kabashima K. Drug-induced hypersensitivity syndrome complicated with concurrent fulminant type 1 diabetes mellitus and Hashimoto’s thyroiditis. Int J Dermatol. 2013;52:355–7.  https://doi.org/10.1111/j.1365-4632.2011.05213.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Aida K, Nishida Y, Tanaka S, Maruyama T, Shimada A, Awata T, Suzuki M, Shimura H, Takizawa S, Ichijo M, Akiyama D, Furuya F, Kawaguchi A, Kaneshige M, Itakura J, Fujii H, Endo T, Kobayashi T. RIG-I-and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes. 2011;60:884–9.  https://doi.org/10.2337/db10-0795.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mizutani T, Yoshimoto T, Kaneko R, Ishii A. Diagnosis of fulminant type 1 diabetes mellitus in an autopsy case with postmortem changes. Leg Med (Tokyo). 2011;13:250–3.  https://doi.org/10.1016/j.legalmed.2011.05.007.CrossRefGoogle Scholar
  24. 24.
    Shibasaki S, Imagawa A, Tauriainen S, Iino M, Oikarinen M, Abiru H, Tamaki K, Seino H, Nishi K, Takase I, Okada Y, Uno S, Murase-Mishiba Y, Terasaki J, Makino H, Shimomura I, Hyöty H, Hanafusa T. Expression of toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr J. 2010;57:211–9.CrossRefGoogle Scholar
  25. 25.
    Wang Z, Zheng Y, Hou C, Yang L, Li X, Lin J, Huang G, Lu Q, Wang CY, Zhou Z. DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun. 2013;41:50–9.  https://doi.org/10.1016/j.jaut.2013.01.009.CrossRefPubMedGoogle Scholar
  26. 26.
    Adachi J, Mimura M, Gotyo N, Watanabe T. The development of fulminant type 1 diabetes during chemotherapy for rectal cancer. Intern Med. 2015;54:819–22.  https://doi.org/10.2169/internalmedicine.54.3413.CrossRefPubMedGoogle Scholar
  27. 27.
    Gaudy C, Clévy C, Monestier S, Dubois N, Préau Y, Mallet S, Richard MA, Grob JJ, Valéro R, Béliard S. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015;38:e182–3.  https://doi.org/10.2337/dc15-1331.CrossRefPubMedGoogle Scholar
  28. 28.
    Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55–7.  https://doi.org/10.2337/dc14-2349.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Onuma H, Tohyama M, Imagawa A, Hanafusa T, Kobayashi T, Kano Y, Ohashi J, Hashimoto K, Osawa H, Makino H, Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research, Japanese Dermatological Association. High frequency of HLA B62 in fulminant type l diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277–81.  https://doi.org/10.1210/jc.2012-2054.CrossRefPubMedGoogle Scholar
  30. 30.
    Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, Sato H, Fujita T, Kaneko T, Asano Y, Kikuchi K. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA. 2001;285:1153–4.  https://doi.org/10.1001/jama.285.9.1153.CrossRefPubMedGoogle Scholar
  31. 31.
    Imagawa A, Hanafusa T. Fulminant type 1 diabetes mellitus. Endocr J. 2006;53:577–84.CrossRefGoogle Scholar
  32. 32.
    Murase Y, Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy--a nationwide 5-year-study in Japan. Diabetologia. 2007;50:531–7.  https://doi.org/10.1007/s00125-006-0575-y.CrossRefPubMedGoogle Scholar
  33. 33.
    Koyano HM, Matsumoto T. Recovery from exocrine pancreatic insufficiency in a patient with fulminant type 1 diabetes. Intern Med. 2013;52:573–5.  https://doi.org/10.2169/internalmedicine.52.9019.CrossRefPubMedGoogle Scholar
  34. 34.
    Yamashita K, Sato Y, Seki K, Asano J, Funase Y, Yamauchi K, Aizawa T. Fulminant type 1 diabetes with robust recovery of insulin secretion: a case report. Diabetes Res Clin Pract. 2013;100:e34–8.  https://doi.org/10.1016/j.diabres.2013.01.032.CrossRefPubMedGoogle Scholar
  35. 35.
    Kaneko K, Satake C, Yamamoto J, Takahashi H, Sawada S, Imai J, Yamada T, Katagiri H. A case of idiopathic type 1 diabetes with subsequent recovery of endogenous insulin secretion despite initial diagnosis of fulminant type 1 diabetes. Endocr J. 2017;64:369–74.  https://doi.org/10.1507/endocrj.EJ16-0245.CrossRefPubMedGoogle Scholar
  36. 36.
    Chinese Diabetes Society. Chinese clinical guideline for continuous glucose monitoring (2012). Chin Med J. 2012;125:4167–74.  https://doi.org/10.3760/cma.j.issn.0366-6999.2012.23.002.CrossRefGoogle Scholar
  37. 37.
    Melki V, Ayon F, Fernandez M, Hanaire-Broutin H. Value and limitations of the Continuous Glucose Monitoring System in the management of type 1 diabetes. Diabetes Metab. 2006;32:123–9.CrossRefGoogle Scholar
  38. 38.
    Cheyne EH, Kerr D. Making “sense” of diabetes: using a continuous glucose sensor in clinical practice. Diabetes Metab Res Rev. 2002;18(Suppl 1):43–8.  https://doi.org/10.1002/dmrr.209.CrossRefGoogle Scholar
  39. 39.
    Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001;24:1858–62.CrossRefGoogle Scholar
  40. 40.
    Edelman SV, Bailey TS. Continuous glucose monitoring health outcomes. Diabetes Technol Ther. 2009;11(Suppl 1):68–74.  https://doi.org/10.1089/dia.2009.0012.CrossRefGoogle Scholar
  41. 41.
    Schaepelynck-Bélicar P, Vague P, Simonin G, Lassmann-Vague V. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab. 2003;29:608–12.CrossRefGoogle Scholar
  42. 42.
    Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24:2030–4.CrossRefGoogle Scholar
  43. 43.
    Jensen MH, Christensen TF, Tarnow L, Seto E, Dencker Johansen M, Hejlesen OK. Real-time hypoglycemia detection from continuous glucose monitoring data of subjects with type 1 diabetes. Diabetes Technol Ther. 2013;15:538–43.  https://doi.org/10.1089/dia.2013.0069.CrossRefPubMedGoogle Scholar
  44. 44.
    Bhide M, Grey JM, Moser EG, Garg SK. A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013;15:533–7.  https://doi.org/10.1089/dia.2013.0169.CrossRefPubMedGoogle Scholar
  45. 45.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33:17–22.  https://doi.org/10.2337/dc09-1502.CrossRefGoogle Scholar
  46. 46.
    Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34:795–800.  https://doi.org/10.2337/dc10-1989.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet Med. 2003;20:1012–5.  https://doi.org/10.1046/j.1464-5491.2003.01037.x.CrossRefPubMedGoogle Scholar
  48. 48.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76.  https://doi.org/10.1056/NEJMoa0805017.CrossRefGoogle Scholar
  49. 49.
    Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011;34:574–9.  https://doi.org/10.2337/dc10-1852.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, Chase HP, Hirsch I, Kollman C, Laffel L, Lawrence JM, Milaszewski K, Ruedy KJ, Tamborlane WV. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32:1947–53.  https://doi.org/10.2337/dc09-0889.CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA, STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20.  https://doi.org/10.1056/NEJMoa1002853.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Scientific and Technical Publishers 2018

Authors and Affiliations

  1. 1.Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes InstituteShanghai Jiao Tong University, Affiliated Sixth People’s HospitalShanghaiChina

Personalised recommendations